Risk Factors of Supply Chain in Biopharmaceutical Companies in Iran

Abbasian, Hadi; Zenouz, Reza Yousefi; Abdollahiasl, Akbar; Toroski, Mahdi; Nikfar, Shekoufeh; Siahi‐Shadbad, Mohammadreza; Kebriaeezadeh, Abbas

doi:10.34172/ps.2020.93

Cited by 4 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Low trust in domestic products, market challenges particularly at the international level, and demand changes are the most common marketing-related concerns (Abbasian et al 2021). Table 9 shows the explanations of each subindicators as part of marketing risk indicator.…”

Section: Marketingmentioning

confidence: 99%

“…The cosmetic supply chain faces fundamental and structural vulnerabilities as a result of macro issues (Abbasian et al 2021).Table 10 shows the explanations of each sub-indicators as part of macro risk indicator. The occurrence of a pandemic can cause delays in business activities both within one country and across countries due to social restrictions…”

Section: Macromentioning

confidence: 99%

“…Financial risk is one of the important supply chain. Cash cycle is important to maintain because it is the main support for running production (Abbasian et al 2021).…”

Section: Supply Chain Risk Indicators Supply Chain Sub-indicators Exp...mentioning

confidence: 99%

See 2 more Smart Citations

Assessing the Supply Chain Risk in Indonesian Cosmetic Industryl

Putri¹,

Ardi²

2022

Proceedings of the International Conference on Industrial Engineering and Operations Management

View full text Add to dashboard Cite

The trend of using cosmetic products in Indonesia is not only exclusively for women but also has expanded for men and children. Until 2019, the Indonesian government recorded 797 domestic cosmetic companies from small, medium, and large scale, which increased compared to 760 companies in the previous year. The cosmetics industry's performance also grew by 5.59% in 2020 and contributed to foreign exchange for export with USD 317 million, increasing 15.2% compared to the previous year. Supply chain flow in business activities is undoubtedly a complicated issue to discuss because the activities, connections, and interrelationships between elements from upstream to downstream are full of risks and uncertainties. This study aims to conceptualize a supply chain risk model in the Indonesian cosmetics industry to ensure the development of appropriate risk mitigation strategy. This research used qualitative data in a questionnaire assessment by experts, processed using a Content Validity Index (CVI) approach. A total of 20 sub-indicators have been successfully validated from 36 sub-indicators by five experts in the cosmetics industry with an average I-CVI value of 0.91.

show abstract

Section: Marketingmentioning

confidence: 99%

Section: Macromentioning

confidence: 99%

See 1 more Smart Citation

Assessing the Supply Chain Risk in Indonesian Cosmetic Industryl

Putri¹,

Ardi²

2022

Proceedings of the International Conference on Industrial Engineering and Operations Management

View full text Add to dashboard Cite

show abstract

“…Its purpose is to review and approve authorized and marketable drugs. [ 7 ] However, the pharmaceutical sector and knowledge-based enterprises have long raised concerns about the Iran Food and Drug Administration’s (IFDA) stringent approach to admitting new drugs to the official drug list, influenced by political, social, and economic factors. Paradoxically, even though the development and acquisition of patent-covered drugs are feasible due to Iran nonmembership in the World Trade Organization (WTO), these strict policies have hindered not only the inclusion of new drugs in the official drug list but also the potential for export.…”

Section: Introductionmentioning

confidence: 99%

Assessing drug lag in new drug approvals by the Iran Food and Drug Administration compared to the U.S. FDA, EMA, and PMDA: A 20-year analysis (2001–2021)

Alipour,

Nadimi Parashkouhi,

Mojahedian

et al. 2024

Medicine

View full text Add to dashboard Cite

The pharmaceutical industry is vital for healthcare advancement through innovative medications, improving lives. A substantial challenge is “Drug lag,” hindering patient access and increasing disease adjusted life years burdens. We aim to examine drug lag for Iran Food and Drug Administration (IFDA) approved drugs versus US Food & Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) over 2001 to 2021. We reviewed new molecular entities within this period, using descriptive statistics in Excel 2019. Drug lag is assessed from relative and absolute perspectives, considering approval gaps and annual rates. Among 710 FDA-approved drugs, 410 received EMA approval, 344 from PMDA, and 148 from IFDA. For 148 IFDA and FDA-approved drugs, the maximum drug lag was 237 months. The mean relative drug lag was 65.18 ± 61.56 months. Compared to EMA (112 drugs), the maximum lag was 257 months, with a mean relative lag of 70.29 ± 53.67 months. With PMDA (127 drugs), the maximum lag was 253 months, with a mean relative lag of 38.23 ± 60.57 months. Iran faces significant drug lag compared to developed countries’ regulatory bodies, limiting patient access to innovative treatments. Addressing this issue is crucial for timely drug access, reducing disease burdens. Further research and policy interventions are needed to mitigate drug lag’s impact on Iran healthcare landscape.

show abstract